Open an account

Mirum Pharmaceuticals

MIRM · NASDAQ

$85.07+$2.83 (+3.44%)TodayMarket closed ·
Prev close $82.24

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Employees
369
Headquarters
Foster City, California
Listed
Jul 18, 2019
Sector
Health Care
Industry
Biotechnology
Website
mirumpharma.com

MIRM key statistics

Market cap
5.52B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
818.81K
Volume
633.34K
Open price
$82.75
High today
$85.55
Low today
$82.32
52 Week high
$130.00
52 Week low
$63.23

Mirum Pharmaceuticals (MIRM) at a glance

Mirum Pharmaceuticals (MIRM) last traded at $85.07, with a market cap of 5.52B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $82.32 and $85.55. The current price is 3.3% above the day's low and 0.6% below its high.

Volume so far is 633.34K shares, below the average of 818.81K shares a day.

Over the past year Mirum Pharmaceuticals has ranged from $63.23 to $130.00, and now sits 33% of the way up that range.

Mirum Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.06 per share against an estimate of -$0.6944.

The average analyst price target is $151.43, 78.0% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 15 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $151.43
Low
$127.26
Now
$85.07
High
$204.75

MIRM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 59.7% on average.

  1. Q3 FY24: reported -$0.30 per share against an estimate of -$0.4583
  2. Q4 FY24: reported -$0.49 per share against an estimate of -$0.2457
  3. Q1 FY25: reported -$0.30 per share against an estimate of -$0.3359
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.333
  5. Q3 FY25: reported $0.05 per share against an estimate of -$0.168
  6. Q4 FY25: reported -$0.10 per share against an estimate of $0.0433
  7. Q1 FY26: reported -$1.08 per share against an estimate of -$0.3604
  8. Q2 FY26: reported -$1.06 per share against an estimate of -$0.6944

MIRM news

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Vandana Singh

    Why Is Mirum Pharmaceuticals Stock Gaining Monday?

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

  • Vandana Singh

    Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

  • Press releaseBusiness Wire

    Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Similar companies

Companies in the same industry as Mirum Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.